Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy

The beneficial cardiorenal outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) have been substantiated by multiple clinical trials, resulting in increased interest in the multifarious pathways by which their mechanisms act. The principal ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Nashawi, Mouhamed, Ahmed, Mahmoud S, Amin, Toka, Abualfoul, Mujahed, Chilton, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716977/
https://www.ncbi.nlm.nih.gov/pubmed/35070111
http://dx.doi.org/10.4330/wjc.v13.i12.676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716977/
https://www.ncbi.nlm.nih.gov/pubmed/35070111
http://dx.doi.org/10.4330/wjc.v13.i12.676

Ejemplares similares